ANI Pharmaceuticals finalized its acquisition of Alimera Sciences, according to a press release.
The acquisition is part of ANI’s bid to grow its rare disease business as well as bolster its position in ophthalmology, according to the release. Under the agreement, ANI bought Alimera’s outstanding shares for $5.50 per share and repaid approximately $72.5 million of Alimera’s debt.
ANI acquired Alimera’s Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) for diabetic macular edema treatment and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) for